Paclitaxel Treatment Options

A collection of 2016 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.

Home

All Treatments

Paclitaxel

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

NCT05325632

Recruiting

The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor receptor 2) positive breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/28/2025

Locations: Moffitt Cancer Center, Tampa, Florida

Conditions: HER2-positive Breast Cancer

Learn More ›

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

NCT05543629

Terminated

The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona +31 locations

Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona

Local Institution - 0096, Costa Mesa, California

Local Institution - 0075, Orange, California

Mayo Clinic in Florida, Jacksonville, Florida

Local Institution - 0027, Orlando, Florida

Local Institution - 0029, Fort Wayne, Indiana

Local Institution - 0022, New Orleans, Louisiana

Local Institution - 0005, Grand Rapids, Michigan

Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota

Local Institution - 0003, Hackensack, New Jersey

Carolina BioOncology Institute, Huntersville, North Carolina

Local Institution - 0019, Cincinnati, Ohio

Local Institution - 0046, Allentown, Pennsylvania

Local Institution - 0016, Houston, Texas

Local Institution - 0018, Darlinghurst, New South Wales

Local Institution - 0001, Westmead, New South Wales

Local Institution - 0086, Southport, Queensland

Local Institution - 0002, Clayton, Victoria

Local Institution - 0084, Murdoch, Western Australia

Local Institution - 0065, Milan, Milano

Local Institution - 0064, Candiolo, Torino

Local Institution - 0077, Siena, Toscana

Local Institution - 0062, Napoli, Not set

Local Institution - 0067, Warszawa, Mazowieckie

Local Institution - 0073, Gdańsk, Pomorskie

Local Institution - 0069, Bydgoszcz, Not set

Local Institution - 0080, Barcelona, Barcelona [Barcelona]

Local Institution - 0083, Madrid, Madrid, Comunidad De

Local Institution - 0079, Madrid, Madrid, Comunidad De

Local Institution - 0082, Málaga, Not set

Local Institution - 0087, Sevilla, Not set

Local Institution - 0081, València, Not set

Conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer

Learn More ›

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

NCT05276973

Active Not Recruiting

This phase I/IB trial tests the safety, side effects, and best dose of ipatasertib in combination with paclitaxel and carboplatin in treating patients with stage III or IV epithelial ovarian cancer. Ipatasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Paclitaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compou... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: UCSF Medical Center-Mission Bay, San Francisco, California +7 locations

Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Unresectable Fallopian Tube Endometrioid Adenocarcinoma, Unresectable Fallopian Tube High Grade Serous Adenocarcinoma, Unresectable Ovarian Endometrioid Adenocarcinoma, Unresectable Ovarian High Grade Serous Adenocarcinoma, Unresectable Primary Peritoneal Endometrioid Adenocarcinoma, Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma

Learn More ›

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738

Recruiting

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Research Site, Springdale, Arkansas +263 locations

Research Site, Springdale, Arkansas

Research Site, Beverly Hills, California

Research Site, Glendale, California

Research Site, Los Alamitos, California

Research Site, San Francisco, California

Research Site, Walnut Creek, California

Research Site, West Haven, Connecticut

Research Site, Newark, Delaware

Research Site, Bay Pines, Florida

Research Site, Gainesville, Florida

Research Site, Jacksonville, Florida

Research Site, Athens, Georgia

Research Site, Atlanta, Georgia

Research Site, Boise, Idaho

Research Site, Chicago, Illinois

Research Site, Decatur, Illinois

Research Site, Quincy, Illinois

Research Site, Waterloo, Iowa

Research Site, Lexington, Kentucky

Research Site, Louisville, Kentucky

Research Site, Covington, Louisiana

Research Site, Shreveport, Louisiana

Research Site, Baltimore, Maryland

Research Site, Detroit, Michigan

Research Site, Grand Rapids, Michigan

Research Site, Duluth, Minnesota

Research Site, Rochester, Minnesota

Research Site, Bridgeton, Missouri

Research Site, Columbia, Missouri

Research Site, Omaha, Nebraska

Research Site, Camden, New Jersey

Research Site, East Syracuse, New York

Research Site, Westbury, New York

Research Site, Cincinnati, Ohio

Research Site, Bend, Oregon

Research Site, Medford, Oregon

Research Site, Salem, Oregon

Research Site, York, Pennsylvania

Research Site, Sioux Falls, South Dakota

Research Site, Chattanooga, Tennessee

Research Site, Nashville, Tennessee

Research Site, Fort Worth, Texas

Research Site, Houston, Texas

Research Site, Kingwood, Texas

Research Site, Lubbock, Texas

Research Site, Round Rock, Texas

Research Site, Fairfax, Virginia

Research Site, Fredericksburg, Virginia

Research Site, Olympia, Washington

Research Site, Seattle, Washington

Research Site, Silverdale, Washington

Research Site, Tacoma, Washington

Research Site, Wenatchee, Washington

Research Site, Buenos Aires, Not set

Research Site, La Plata, Not set

Research Site, Pilar, Not set

Research Site, Rosario, Not set

Research Site, Innsbruck, Not set

Research Site, Krems, Not set

Research Site, Rankweil, Not set

Research Site, Wien, Not set

Research Site, Anderlecht, Not set

Research Site, Brussels, Not set

Research Site, Charleroi, Not set

Research Site, Kortrijk, Not set

Research Site, Sint-Niklaas, Not set

Research Site, Barretos, Not set

Research Site, Florianópolis, Not set

Research Site, Ijuí, Not set

Research Site, Londrina, Not set

Research Site, Porto Alegre, Not set

Research Site, Salvador, Not set

Research Site, Sao Paulo, Not set

Research Site, Taubaté, Not set

Research Site, Saint John, New Brunswick

Research Site, Sydney, Nova Scotia

Research Site, Hamilton, Ontario

Research Site, Montreal, Quebec

Research Site, Montréal, Quebec

Research Site, Beijing, Not set

Research Site, Changchun, Not set

Research Site, Changde, Not set

Research Site, Changsha, Not set

Research Site, Chengdu, Not set

Research Site, Chongqing, Not set

Research Site, Dalian, Not set

Research Site, Guangzhou, Not set

Research Site, Hangzhou, Not set

Research Site, Harbin, Not set

Research Site, Hefei, Not set

Research Site, Jinan, Not set

Research Site, Kunming, Not set

Research Site, Linhai, Not set

Research Site, Linyi, Not set

Research Site, Nanchang, Not set

Research Site, Ningbo, Not set

Research Site, Shanghai, Not set

Research Site, Shenyang, Not set

Research Site, Shenzhen, Not set

Research Site, Taiyuan, Not set

Research Site, Tianjin, Not set

Research Site, Wenzhou, Not set

Research Site, Wuhan, Not set

Research Site, Xi'an, Not set

Research Site, Yangzhou, Not set

Research Site, Yueyang, Not set

Research Site, Zhengzhou, Not set

Research Site, Avignon, Not set

Research Site, La Rochelle Cedex, Not set

Research Site, Lyon, Not set

Research Site, Nimes, Not set

Research Site, Rennes, Not set

Research Site, Strasbourg Cedex, Not set

Research Site, Suresnes, Not set

Research Site, Toulon Cedex 9, Not set

Research Site, Bad Berka, Not set

Research Site, Berlin, Not set

Research Site, Esslingen, Not set

Research Site, Frankfurt, Not set

Research Site, Gauting, Not set

Research Site, Giessen, Not set

Research Site, Großhansdorf, Not set

Research Site, Hamburg, Not set

Research Site, Hannover, Not set

Research Site, Heidelberg, Not set

Research Site, Hemer, Not set

Research Site, Homburg, Not set

Research Site, Kassel, Not set

Research Site, Kiel, Not set

Research Site, Krefeld, Not set

Research Site, Köln, Not set

Research Site, Minden, Not set

Research Site, Moers, Not set

Research Site, München, Not set

Research Site, Regensburg, Not set

Research Site, Würzburg, Not set

Research Site, Budapest, Not set

Research Site, Debrecen, Not set

Research Site, Gyöngyös, Not set

Research Site, Győr, Not set

Research Site, Pécs, Not set

Research Site, Székesfehérvár, Not set

Research Site, Törökbálint, Not set

Research Site, Calicut, Not set

Research Site, Delhi, Not set

Research Site, Kolkata, Not set

Research Site, Madurai, Not set

Research Site, Mumbai, Not set

Research Site, Nashik, Not set

Research Site, New Delhi, Not set

Research Site, Pondicherry, Not set

Research Site, Surat, Not set

Research Site, Varanasi, Not set

Research Site, Firenze, Not set

Research Site, Monza, Not set

Research Site, Padova, Not set

Research Site, Peschiera Del Garda, Not set

Research Site, Roma, Not set

Research Site, Amagasaki-shi, Not set

Research Site, Bunkyo-ku, Not set

Research Site, Chuo-ku, Not set

Research Site, Fukuoka-shi, Not set

Research Site, Hiroshima-shi, Not set

Research Site, Kawagoe-shi, Not set

Research Site, Kitaadachi-gun, Not set

Research Site, Kitakyushu-shi, Not set

Research Site, Kobe-shi, Not set

Research Site, Koto-ku, Not set

Research Site, Kumamoto-shi, Not set

Research Site, Matsusaka-shi, Not set

Research Site, Osaka-shi, Not set

Research Site, Osakasayama, Not set

Research Site, Ota-shi, Not set

Research Site, Saitama-shi, Not set

Research Site, Sendai-shi, Not set

Research Site, Shinjuku-ku, Not set

Research Site, Yokohama-shi, Not set

Research Site, Cheongju-si, Not set

Research Site, Incheon, Not set

Research Site, Seoul, Not set

Research Site, Suwon-si, Not set

Research Site, George Town, Not set

Research Site, Johor Bahru, Not set

Research Site, Kuala Lumpur, Not set

Research Site, Alkmaar, Not set

Research Site, Groningen, Not set

Research Site, Utrecht, Not set

Research Site, Veldhoven, Not set

Research Site, Zwolle, Not set

Research Site, Lima, Not set

Research Site, Biała Podlaska, Not set

Research Site, Białystok, Not set

Research Site, Bydgoszcz, Not set

Research Site, Bystra, Not set

Research Site, Poznań, Not set

Research Site, Warszawa, Not set

Research Site, Łódź, Not set

Research Site, San Juan, Not set

Research Site, Barcelona, Not set

Research Site, Las Palmas de Gran Canaria, Not set

Research Site, Lérida, Not set

Research Site, Madrid, Not set

Research Site, Majadahonda, Not set

Research Site, Sevilla, Not set

Research Site, Kaohsiung, Not set

Research Site, New Taipei City, Not set

Research Site, New Taipei, Not set

Research Site, Taichung, Not set

Research Site, Tainan City, Not set

Research Site, Taoyuan, Not set

Research Site, Bangkok, Not set

Research Site, Chiang Mai, Not set

Research Site, Dusit, Not set

Research Site, Nakhon Ratchasima, Not set

Research Site, Songkla, Not set

Research Site, Antalya, Not set

Research Site, Istanbul, Not set

Research Site, Yenimahalle, Not set

Research Site, Aberdeen, Not set

Research Site, Cambridge, Not set

Research Site, Edinburgh, Not set

Research Site, Exeter, Not set

Research Site, Greater London, Not set

Research Site, London, Not set

Research Site, Manchester, Not set

Research Site, Newcastle upon Tyne, Not set

Research Site, Preston, Not set

Research Site, Can Tho, Not set

Research Site, Hanoi, Not set

Research Site, Ho Chi Minh city, Not set

Research Site, Ho Chi Minh, Not set

Research Site, Vinh, Not set

Conditions: Non-small Cell Lung Cancer

Learn More ›

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

NCT04623775

Active Not Recruiting

The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Local Institution - 0160, Duarte, California +124 locations

Local Institution - 0160, Duarte, California

Local Institution - 0081, Orange, California

Local Institution - 0139, New Haven, Connecticut

Local Institution - 0153, Jacksonville, Florida

Local Institution - 0011, Port Saint Lucie, Florida

Local Institution - 0089, Athens, Georgia

Local Institution - 0121, Wichita, Kansas

Local Institution - 0159, Lexington, Kentucky

Local Institution - 0002, Louisville, Kentucky

Local Institution - 0082, Scarborough, Maine

Local Institution - 0129, Omaha, Nebraska

Local Institution - 0152, Howell, New Jersey

Local Institution - 0097, Bronx, New York

Local Institution - 0124, Johnson City, New York

Local Institution - 0162, Mineola, New York

Local Institution - 0128, New York, New York

Local Institution - 0165, New York, New York

Local Institution - 0117, Durham, North Carolina

Local Institution - 0156, Cincinnati, Ohio

Local Institution - 0155, Cleveland, Ohio

Local Institution - 0084, Lancaster, Pennsylvania

Local Institution - 0147, Pittsburgh, Pennsylvania

Local Institution - 0148, Providence, Rhode Island

Local Institution - 0083, Greenville, South Carolina

Local Institution - 0149, Dallas, Texas

Local Institution - 0091, Harlingen, Texas

Local Institution - 0001, Tyler, Texas

Local Institution - 0092, Spokane, Washington

Local Institution - 0157, Morgantown, West Virginia

Local Institution - 0037, Río Cuarto, Cordoba

Local Institution - 0021, Buenos Aires, Distrito Federal

Local Institution - 0014, Cuiudad Autonoma De Buenos Aires, Distrito Federal

Local Institution - 0039, Viedma, RIO Negro

Local Institution - 0029, Rosario, Santa Fe

Local Institution - 0060, Cordoba, Not set

Local Institution - 0038, Cordoba, Not set

Local Institution - 0073, La Rioja, Not set

Local Institution - 0055, Camperdown, New South Wales

Local Institution - 0086, Gosford, New South Wales

Local Institution - 0132, Tamworth, New South Wales

Local Institution - 0057, Adelaide, South Australia

Local Institution - 0130, Ballarat, Victoria

Local Institution - 0138, Bendigo, Victoria

Local Institution - 0141, Box Hill, Victoria

Local Institution - 0109, Frankston, Victoria

Local Institution - 0119, Murdoch, Western Australia

Local Institution - 0085, Nedlands, Western Australia

Local Institution - 0090, Graz, Not set

Local Institution - 0126, Vienna, Not set

Local Institution - 0127, Ghent, Not set

Local Institution - 0131, Ghent, Not set

Local Institution - 0125, Roeselare, Not set

Local Institution - 0063, Natal, Rio Grande Do Norte

Local Institution - 0161, Ijui, Rio Grande Do Sul

Local Institution - 0116, Porto Alegre, RIO Grande DO SUL

Local Institution - 0112, Porto Alegre, RIO Grande DO SUL

Local Institution - 0107, Barretos, Sao Paulo

Local Institution - 0111, Santo Andre, SAO Paulo

Local Institution - 0072, Rio de Janeiro, Not set

Local Institution - 0163, Sao Paulo, Not set

Local Institution - 0120, Sao Paulo, Not set

Local Institution - 0079, Santiago de Chile, Metropolitana

Local Institution - 0041, Santiago, Metropolitana

Local Institution - 0016, Santiago, Metropolitana

Local Institution - 0110, Paris, Ile De France

Local Institution - 0008, Rennes, Ille-Et-Vilaine

Local Institution - 0007, Dijon, Not set

Local Institution - 0144, Le Mans, Not set

Local Institution - 0102, Paris, Not set

Local Institution - 0035, Paris, Not set

Local Institution - 0006, Saint-Mande, Not set

Local Institution - 0065, Essen, NRW

Local Institution - 0103, Berlin, Not set

Local Institution - 0045, Berlin, Not set

Local Institution - 0062, Grosshansdorf, Not set

Local Institution - 0058, Homburg, Not set

Local Institution - 0108, Lowenstein, Not set

Local Institution - 0071, Marburg, Not set

Local Institution - 0050, Paderborn, Not set

Local Institution - 0030, Ravensburg, Not set

Local Institution - 0133, Elm Park, Dublin

Local Institution - 0023, Dublin, Not set

Local Institution - 0106, Rome, RA

Local Institution - 0028, Candiolo, Not set

Local Institution - 0009, Catania, Not set

Local Institution - 0032, Genova, Not set

Local Institution - 0059, Milano, Not set

Local Institution - 0164, Pesaro, Not set

Local Institution - 0019, Siena, Not set

Local Institution - 0070, Ciudad de Mexico, Distrito Federal

Local Institution - 0020, Toluca de Lerdo, Estado DE Mexico

Local Institution - 0115, Monterrey, Nuevo LEON

Local Institution - 0013, San Pedro Garza Garcia, Nuevo LEON

Local Institution - 0053, Harderwijk, Gelderland

Local Institution - 0158, Arnhem, Not set

Local Institution - 0145, Gdynia, Not set

Local Institution - 0036, Lublin, Not set

Local Institution - 0031, Lublin, Not set

Local Institution - 0080, Olsztyn, Not set

Local Institution - 0088, Warszawa, Not set

Local Institution - 0099, Cluj Napoca, Cluj

Local Institution - 0017, Craiova, Dolj

Local Institution - 0012, Craiova, Jud. Dolj

Local Institution - 0069, Timisoara, Timis

Local Institution - 0052, Craiova, Not set

Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Not set

FSBI &quot,Research Institute of Influenza named after A.A. Smorodintsev &quot,of the MoH of the Rus, Saint Petersburg, Not set

LLC Eurocityclinic, Saint-Petersburg, Not set

Local Institution - 0075, Sevilla, Andalucia

Local Institution - 0137, Badalona, Barcelona

Local Institution - 0024, Barcelona, Cataluna

Local Institution - 0051, A Coruna, Not set

Local Institution - 0154, Barcelona, Not set

Local Institution - 0048, Barcelona, Not set

Local Institution - 0061, Las Palmas, Not set

Local Institution - 0074, Madrid, Not set

Local Institution - 0123, Madrid, Not set

Local Institution - 0042, Malaga, Not set

Local Institution - 0043, Valencia, Not set

Local Institution - 0015, Basel, Not set

Local Institution - 0104, St. Gallen, Not set

Local Institution - 0135, Middlesborough, Cleveland

Local Institution - 0101, London, Greater London

Local Institution - 0095, Manchester, Lancashire

Local Institution - 0067, Leicester, Not set

Conditions: Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Non-small Cell Lung Cancer

Learn More ›

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337

Recruiting

The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Research Site 1141-0, Tucson, Arizona +184 locations

Research Site 1141-0, Tucson, Arizona

Research Site 1114-0, Fullerton, California

Research Site 1107-0, Los Angeles, California

Research Site 1118-0, Orange, California

Research Site 1143-0, Sacramento, California

Research Site 1132-0, Santa Barbara, California

Research Site 1129-0, Lone Tree, Colorado

Research Site 1125-0, Palm Bay, Florida

Research Site 1110-0, Savannah, Georgia

Research Site 1124-0, Chicago Ridge, Illinois

Research Site 1106-0, Merriam, Kansas

Research Site 1104-0, Louisville, Kentucky

Research Site 1122-0, Silver Spring, Maryland

Research Site 8639-0, Silver Spring, Maryland

Research Site 1109-0, Kansas City, Missouri

Research Site 1111-0, Florham Park, New Jersey

Research Site 1105-0, Westbury, New York

Research Site 1144-0, Chapel Hill, North Carolina

Research Site 1138-0, Akron, Ohio

Research Site 1133-0, Eugene, Oregon

Research Site 1126-0, Tigard, Oregon

Research Site 1134-0, Broomall, Pennsylvania

Research Site 1123-0, Horsham, Pennsylvania

Research Site 1149-0, Knoxville, Tennessee

Research Site 1102-0, Nashville, Tennessee

Research Site 1101-0, Dallas, Texas

Research Site 1116-0, Denison, Texas

Research Site 1115-0, Houston, Texas

Research Site 1117-0, San Antonio, Texas

Research Site 1130-0, Salt Lake City, Utah

Research Site 1108-0, Fairfax, Virginia

Research Site 1131-0, Fairfax, Virginia

Research Site 1127-0, Roanoke, Virginia

Research Site 5401-0, Rosario, Santa Fe

Research Site 5404-0, San Miguel de Tucuman, Tucuman

Research Site 6108-0, Camperdown, New South Wales

Research Site 6109-0, Liverpool, New South Wales

Research Site 6102-0, Sydney, New South Wales

Research Site 6106-0, Birtinya, Queensland

Research Site 6101-0, South Brisbane, Queensland

Research Site 6107-0, Southport, Queensland

Research Site 6104-0, Townsville, Queensland

Research Site 6110-0, Adelaide, South Australia

Research Site 6103-0, Bendigo, Victoria

Research Site 6105-0, St. Albans, Victoria

Research Site 3201-0, Brussels, Not set

Research Site 3204-0, Gent, Not set

Research Site 3205-0, Jette, Not set

Research Site 3203-0, Leuven, Not set

Research Site 3207-0, Liege, Not set

Research Site 3202-0, Roeselare, Not set

Research Site 1003-0, Brampton, Ontario

Research Site 1001-0, Toronto, Ontario

Research Site 1004-0, Montreal, Quebec

Research Site 1005-0, Montreal, Quebec

Research Site 1006-0, Montreal, Quebec

Research Site 1002-0, Sherbrooke, Quebec

Research Site 8640-0, Hefei, Anhui

Research Site 8614-0, Hefei, Anhui

Research Site 8601-0, Beijing, Beijing

Research Site 8625-0, Beijing, Beijing

Research Site 8627-0, Chongqing, Chongqing

Research Site 8651-0, Fuzhou, Fujian

Research Site 8638-0, Xiamen, Fujian

Research Site 8630-0, Lanzhou, Gansu

Research Site 8604-0, Guangzhou, Guangdong

Research Site 8628-0, Guangzhou, Guangdong

Research Site 8621-0, Huizhou, Guangdong

Research Site 8622-0, Zhuhai, Guangdong

Research Site 8615-0, Nanning, Guangxi

Research Site, Baoding, Hebei

Research Site 8629-0, Baoding, Hebei

Research Site 8645-0, Shijiazhuang, Hebei

Research Site 8619-0, Harbin, Heilongjiang

Research Site 8649-0, Anyang, Henan

Research Site 8609-0, Luoyang, Henan

Research Site 8648-0, Weihui, Henan

Research Site 8605-0, Zhengzhou, Henan

Research Site 8623-0, Zhengzhou, Henan

Research Site 8637-0, Wuhan, Hubei

Research Site 8608-0, Wuhan, Hubei

Research Site 8633-0, Xiangyang, Hubei

Research Site 8635-0, Changsha, Hunan

Research Site 8654-0, Yongzhou, Hunan

Research Site 8646-0, Huai'an, Jiangsu

Research Site 8607-0, Nanjing, Jiangsu

Research Site 8624-0, Xuzhou, Jiangsu

Research Site 8631-0, Nanchang, Jiangxi

Research Site 8612-0, Changchun, Jilin

Research Site 8618-0, Changchun, Jilin

Research Site 8644-0, Changchun, Jilin

Research Site 8636-0, Dalian, Liaoning

Research Site-8636-0, Dalian, Liaoning

Research Site 8643-0, Shenyang, Liaoning

Research Site 8642-0, Shenyang, Liaoning

Research Site 8634-0, Jinan, Shandong

Research Site 8613-0, Jining, Shandong

Research Site 8610-0, Linyi, Shandong

Research Site 8650-0, Weihai, Shandong

Research Site 8603-0, Shanghai, Shanghai

Research Site 8602-0, Shanghai, Shanghai

Research Site 8611-0, Xi'an, Shanxi

Research Site 8606-0, Chengdu, Sichuan

Research Site 8626-0, Neijiang, Sichuan

Research Site 8647-0, Zigong, Sichuan

Research Site 8617-0, Tianjin, Tianjin

Research Site 8616-0, Urumqi, Xinjiang

Research Site 8632-0, Kunming, Yunnan

Research Site 8652-0, Hangzhou, Zhejiang

Research Site 8620-0, Hangzhou, Zhejiang

Research Site 8641-0, Hangzhou, Zhejiang

Research Site 3311-0, Marseille cedex 20, Bouches-du-Rhône

Research Site 3303-0, La Rochelle cedex, Charente Maritime

Research Site 3312-0, Besancon Cedex, Doubs

Research Site 3308-0, Nimes, Gard

Research Site 3314-0, Bordeaux, Gironde

Research Site 3305-0, Toulouse cedex 09, Haute Garonne

Research Site 3309-0, Limoges, Haute Vienne

Research Site 3304-0, Montpellier, Herault

Research Site 3310-0, Saint Herblain, Loire Atlantique

Research Site 3301-0, Angers Cedex 2, Maine Et Loire

Research Site 3315-0, Lille cedex, Nord

Research Site 3306-0, Bayonne cedex, Pyrenees Atlantiques

Research Site 3318-0, Pierre Benite cedex, Rhone

Research Site 3313-0, Rouen, Seine Maritime

Research Site 3307-0, Avignon Cedex 9, Vaculuse

Research Site 3302-0, Creteil Cedex, Val De Marne

Research Site 3316-0, Paris, Not set

Research Site 4904-0, Bottrop, Nordrhein Westfalen

Research Site 8501-0, Hong Kong, Not set

Research Site 8503-0, Hong Kong, Not set

Research Site 8502-0, Hong Kong, Not set

Research Site 8505-0, Hong Kong, Not set

Research Site 3603-0, Budapest, Not set

Research Site 3606-0, Gyor, Not set

Research Site 3604-0, Kecskemet, Not set

Research Site 3602-0, Salgotarjan, Not set

Research Site 3607-0, Tatabanya, Not set

Research Site 9702-0, Jerusalem, Not set

Research Site 9703-0, Kfar-Saba, Not set

Research Site 9704-0, Petach-Tikva, Not set

Research Site 9705-0, Rehovot, Not set

Research Site 3908-0, Bergamo, Not set

Research Site 3907-0, Brescia, Not set

Research Site 3901-0, Catania, Not set

Research Site 3903-0, Catanzaro, Not set

Research Site 3906-0, Milano, Not set

Research Site 3911-0, Milano, Not set

Research Site 3904-0, Milano, Not set

Research Site 3909-0, Napoli, Not set

Research Site 3905-0, Verona, Not set

Research Site 8211-0, Wonju, Gangwon-do

Research Site 8204-0, Seongnam, Gyeonggi-do

Research Site 8201-0, Seoul, Gyeonggi-do

Research Site 8202-0, Suwon, Gyeonggi-do

Research Site 8208-0, Busan, Not set

Research Site 8209-0, Incheon, Not set

Research Site 8207-0, Seoul, Not set

Research Site 8206-0, Seoul, Not set

Research Site 8210-0, Seoul, Not set

Research Site 8203-0, Seoul, Not set

Research Site 8205-0, Seoul, Not set

Research Site 4802-0, Rzeszów, Not set

Research Site 4807-0, Torun, Not set

Research Site 4803-0, Łódź, Not set

Research Site 3403-0, Sant Cugat del Valles, Barcelona

Research Site 3409-0, Santiago de Compostela, La Coruña

Research Site 3406-0, Majadahonda, Madrid

Research Site 3410-0, Barcelona, Not set

Research Site 3402-0, Barcelona, Not set

Research Site 3404-0, Barcelona, Not set

Research Site 3416-0, Madrid, Not set

Research Site 3407-0, Madrid, Not set

Research Site 3414-0, Madrid, Not set

Research Site 3401-0, Madrid, Not set

Research Site 3415-0, Málaga, Not set

Research Site 3408-0, Sevilla, Not set

Research Site 3413-0, Sevilla, Not set

Research Site 3412-0, Valencia, Not set

Research Site 4404-0, Truro, Cornwall

Research Site 4408-0, London, Greater London

Research Site 4409-0, London, Greater London

Research Site 4402-0, Manchester, Greater Manchester

Research Site 4407-0, Leeds, West Yorkshire

Research Site 4401-0, Nottingham, Not set

Conditions: Metastatic Breast Cancer

Learn More ›

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358

Active Not Recruiting

The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer. The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to P... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: University of Alabama at Birmingham-Medicine ( Site 0065), Birmingham, Alabama +255 locations

University of Alabama at Birmingham-Medicine ( Site 0065), Birmingham, Alabama

Arizona Oncology Associates-Arizona Oncology ( Site 0049), Tucson, Arizona

Pacific Cancer Care ( Site 0023), Monterey, California

UCSF Medical Center at Mission Bay ( Site 0043), San Francisco, California

Georgetown University Medical Center-Department of Medicine and Oncology ( Site 0026), Washington, District of Columbia

MedStar Washington Hospital Center ( Site 0063), Washington, District of Columbia

Baptist MD Anderson Cancer Center ( Site 0013), Jacksonville, Florida

Miami Cancer Institute at Baptist Health, Inc. ( Site 0070), Miami, Florida

Miami Cancer Institute - Plantation ( Site 0076), Plantation, Florida

University Cancer & Blood Center, LLC ( Site 0032), Athens, Georgia

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0028), Marietta, Georgia

University of Illinois at Chicago ( Site 0061), Chicago, Illinois

Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W. Knowles Cancer Center ( Site 0067), Elmhurst, Illinois

Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0066), Naperville, Illinois

Edward-Elmhurst Healthcare, Edward Hospital - Plainfield-Edward Cancer Center - Plainfield ( Site 00, Plainfield, Illinois

Orchard Healthcare Research Inc. ( Site 0037), Skokie, Illinois

Parkview Research Center at Parkview Regional Medical Center ( Site 0071), Fort Wayne, Indiana

McFarland Clinic, PC ( Site 0041), Ames, Iowa

Louisiana State University Health Sciences Shreveport ( Site 0072), Shreveport, Louisiana

CHRISTUS Highland-Oncology Research ( Site 0073), Shreveport, Louisiana

New England Cancer Specialists ( Site 0007), Scarborough, Maine

Greater Baltimore Medical Center-Medical Oncology/Hematology ( Site 0062), Baltimore, Maryland

MFSMC-HJWCI ( Site 0064), Baltimore, Maryland

MedStar Good Samaritan Hospital-Oncology Research ( Site 0069), Baltimore, Maryland

University of Massachusetts Medical School-Division of Hematology/Oncology ( Site 0052), Worcester, Massachusetts

Henry Ford Hospital ( Site 0003), Detroit, Michigan

Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0009), Omaha, Nebraska

Broome Oncology ( Site 0018), Johnson City, New York

Hematology Oncology Associates of Rockland ( Site 0044), Nyack, New York

Waverly Hematology Oncology ( Site 0015), Cary, North Carolina

Sanford Fargo Medical Center ( Site 0040), Fargo, North Dakota

Providence Portland Medical Center ( Site 0038), Portland, Oregon

Oregon Health and Science University ( Site 0031), Portland, Oregon

St Francis Cancer Center ( Site 0058), Greenville, South Carolina

Sanford Cancer Center ( Site 0021), Sioux Falls, South Dakota

University of Tennessee Medical Center ( Site 0039), Knoxville, Tennessee

Bon Secours St. Francis Medical Center-Oncology Research ( Site 0020), Midlothian, Virginia

Kadlec Clinic Hematology and Oncology ( Site 0055), Kennewick, Washington

Medical Oncology Associates, PS ( Site 0010), Spokane, Washington

Northwest Medical Specialties, PLLC ( Site 0008), Tacoma, Washington

North Star Lodge ( Site 0035), Yakima, Washington

Centro de Oncología e Investigación de Buenos Aires ( Site 0400), Berazategui, Buenos Aires

Hospital Británico de Buenos Aires-Oncology ( Site 0404), Ciudad autónoma de Buenos Aires, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0412), Mar del Plata, Buenos Aires

Hospital Aleman-Oncology ( Site 0402), Buenos Aires, Caba

Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0403), Buenos Aires, Caba

Sanatorio de La Mujer ( Site 0405), Rosario, Santa Fe

Sanatorio Parque ( Site 0407), Rosario, Santa Fe

Instituto de Oncología de Rosario ( Site 0401), Rosario, Santa Fe

Hospital Italiano de Córdoba ( Site 0409), Cordoba, Not set

Fundación CEMAIC ( Site 0410), Cordoba, Not set

Instituto San Marcos ( Site 0408), San Juan, Not set

Macquarie University-MQ Health Clinical Trials Unit ( Site 2102), Macquarie Park, New South Wales

Westmead Hospital-Department of Medical Oncology ( Site 2101), Westmead, New South Wales

Frankston Hospital-Oncology and Haematology ( Site 2103), Frankston, Victoria

Breast Cancer Research Centre-WA ( Site 2104), Nedlands, Western Australia

Landesklinikum Wiener Neustadt-Innere Medizin, Hämatologie und internistische Onkologie ( Site 1604), Wiener Neustadt, Niederosterreich

Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 1609), Graz, Steiermark

Medizinische Universitaet Innsbruck ( Site 1602), Innsbruck, Tirol

Medizinische Universität Wien ( Site 1601), Vienna, Wien

Uniklinikum Salzburg-Universitätsklinik für Innere Medizin III der PMU mit Hämatologie, internistis, Salzburg, Not set

Hospital de Câncer de Recife ( Site 0211), Recife, Pernambuco

Instituto de Oncologia Saint Gallen ( Site 0206), Santa Cruz do Sul, Rio Grande Do Sul

Clínica de Oncologia Reichow ( Site 0210), Blumenau, Santa Catarina

YNOVA Pesquisa Clínica ( Site 0203), Florianópolis, Santa Catarina

Instituto Nacional de Câncer - INCA-Pesquisa Clinica HC3 ( Site 0208), Rio de Janeiro, Not set

Instituto de Educação, Pesquisa e Gestão em Saúde ( Site 0202), Rio de Janeiro, Not set

Tom Baker Cancer Center ( Site 0107), Calgary, Alberta

North York General Hospital ( Site 0108), Toronto, Ontario

Princess Margaret Cancer Centre ( Site 0101), Toronto, Ontario

Jewish General Hospital ( Site 0110), Montreal, Quebec

Centre Hospitalier de l'Université de Montréal ( Site 0105), Montréal, Quebec

Hopital Du Saint-Sacrement ( Site 0109), Quebec City, Quebec

Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec (, Trois-Rivières, Quebec

Centro Investigación del Cáncer James Lind ( Site 0513), Temuco, Araucania

FALP ( Site 0501), Santiago, Region M. De Santiago

Oncovida ( Site 0514), Santiago, Region M. De Santiago

Clínica RedSalud Vitacura ( Site 0515), Santiago, Region M. De Santiago

Instituto Nacional del Cancer-CR Investigación ( Site 0511), Santiago, Region M. De Santiago

Bradfordhill ( Site 0500), Santiago, Region M. De Santiago

Anhui Cancer Hospital-medical oncology ( Site 2632), Hefei, Anhui

Cancer Hospital Chinese Academy of Medical Science ( Site 2635), Beijing, Beijing

Beijing Cancer hospital-Department of Breast Cancer ( Site 2605), Beijing, Beijing

Beijing Peking Union Medical College Hospital-Medical Oncology ( Site 2610), Beijing, Beijing

The First Affiliated hospital of Xiamen University-Breast Surgery ( Site 2613), Xiamen, Fujian

The First People's Hospital of Foshan-Oncology Department of Breast Cancer ( Site 2620), Foshan, Guangdong

SUN YAT-SEN UNIVERSITY CANCER CENTRE-oncology breast ( Site 2616), Guangzhou, Guangdong

Sun Yat-sen Memorial Hospital, Sun Yat-sen University-Breast Oncology Center ( Site 2641), Guangzhou, Guangdong

Peking University Shenzhen Hospital-Oncology Department ( Site 2601), Shenzhen, Guangdong

Guangxi Medical University Affiliated Tumor Hospital-Oncology Dept. of Breast and Bone Soft Tissue (, Nanning, Guangxi

Henan Cancer Hospital-Galactophore Department ( Site 2615), Zhengzhou, Henan

Wuhan Union Hospital Cancer Center-Cancer Center ( Site 2629), Wuhan, Hubei

Xiangya Hospital Central South University-Breast department ( Site 2621), Changsha, Hunan

Hunan Cancer Hospital ( Site 2608), Changsha, Hunan

Jiangsu provincial people's hospital-Oncology Department ( Site 2607), Nanjing, Jiangsu

The Third Hospital of Nanchang-Oncology Dept ( Site 2628), Nanchang, Jiangxi

Jilin Cancer Hospital-oncology department ( Site 2619), Changchun, Jilin

The First Affiliated Hospital of Xian Jiaotong University wa-Oncology ( Site 2604), Xi'an, Shaanxi

Shandong Cancer Hospital-Breast surgery ( Site 2623), Jinan, Shandong

Fudan University Shanghai Cancer Center-Oncology ( Site 2600), Shanghai, Shanghai

Renji Hospital Shanghai Jiao Tong University School of Medicine-Breast surgery ( Site 2626), Shanghai, Shanghai

West China Hospital Sichuan University-Head and Neck Oncology ( Site 2630), Cheng Du, Sichuan

Tianjin Medical University Cancer Institute and Hospital-Department of Breast Cancer ( Site 2612), Tianjin, Tianjin

Xinjiang Medical University Cancer Hospital - Urumqi-galactophore department ( Site 2624), Urumqi, Xinjiang

Zhejiang Cancer Hospital-Breast Oncology ( Site 2622), Hangzhou, Zhejiang

Taizhou Hospital of Zhejiang Province ( Site 2636), Linhai, Zhejiang

The First Affiliated Hospital of Wenzhou Medical University-Thyroid and breast surgery ( Site 2625), Wenzhou, Zhejiang

Fundación Colombiana de Cancerología Clínica Vida ( Site 0605), Medellín, Antioquia

Instituto de Cancerología-Oncology ( Site 0606), Medellín, Antioquia

Clinica de la Costa S.A.S. ( Site 0601), Barranquilla, Atlantico

Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0603), Valledupar, Cesar

Oncomedica S.A.-Oncomedica S.A ( Site 0604), Montería, Cordoba

Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 0607), Bogota, Distrito Capital De Bogota

Institut Paoli-Calmettes ( Site 0913), Marseille, Bouches-du-Rhone

Centre François Baclesse ( Site 0920), Caen, Calvados

CHU Besançon ( Site 0918), Besançon, Franche-Comte

Institut Claudius Regaud ( Site 0902), Toulouse, Haute-Garonne

Gustave Roussy ( Site 0914), Villejuif, Ile-de-France

Centre de Cancérologie du Grand Montpellier ( Site 0912), Montpellier, Languedoc-Roussillon

Institut de Cancérologie de l'Ouest ( Site 0907), Saint Herblain, Loire-Atlantique

Institut de Cancérologie de l'Ouest ( Site 0915), ANGERS cedex 02, Maine-et-Loire

Centre Oscar Lambret ( Site 0921), Lille, Nord

Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne ( Site 0901), Clermont-Ferrand, Puy-de-Dome

CENTRE LEON BERARD ( Site 0919), Lyon, Rhone-Alpes

Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen ( Site 0904), Rouen, Seine-Maritime

Centre Hospitalier Universitaire de Poitiers-Pôle régional de cancérologie ( Site 0922), Poitiers, Vienne

Institut Curie ( Site 0900), Paris, Not set

Universitaetsklinikum Erlangen-Klinik für Gynäkologie und Geburtshilfe ( Site 1202), Erlangen, Bayern

Gynaekologisches Zentrum Bonn ( Site 1201), Bonn, Nordrhein-Westfalen

Universitaetsklinikum Duesseldorf-Klinik für Frauenheilkunde & Geburtshilfe ( Site 1204), Düsseldorf, Nordrhein-Westfalen

Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung-Klinike für Senologie/ Brustzentrum ( Site 1200, Essen, Nordrhein-Westfalen

Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur, Dresden, Sachsen

Vivantes Klinikum Am Urban-Haematologie und Onkologie ( Site 1203), Berlin, Not set

General Hospital of Athens Laiko-First Department of Internal Medicine ( Site 0305), Athens, Attiki

Alexandra Hospital-ONCOLGOY DEPT. ( Site 0302), Athens, Attiki

Hygeia Hospital-3rd Oncology Department ( Site 0304), Marousi, Attiki

University General Hospital of Heraklion-Internal Medicine-Oncology ( Site 0303), Heraklion, Irakleio

Euromedica General Clinic Thessaloniki-Oncology Unit ( Site 0301), Thessaloniki, Not set

CELAN,S.A ( Site 0151), Guatemala, Not set

Gastrosoluciones ( Site 0156), Guatemala, Not set

INTEGRA Cancer Institute ( Site 0155), Guatemala, Not set

Centro Medico Integral De Cancerología (CEMIC) ( Site 0154), Quetzaltenango, Not set

Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 2804), Kecskemét, Bacs-Kiskun

Pécsi Tudományegyetem Klinikai Központ-Onkoterápiás Intézet ( Site 2807), Pécs, Baranya

Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Onkoterapias Klinika ( Site 2805), Szeged, Csongrad

St. James's Hospital ( Site 1530), Dublin, Not set

St. Vincent's University Hospital-Medical Oncology Research Department ( Site 1531), Dublin, Not set

Assuta Ashdod Medical Center ( Site 1703), Ashdod, Not set

Soroka Medical Center-Oncology ( Site 1702), Be'er Sheva, Not set

Bnai Zion Medical Center-Oncology ( Site 1704), Haifa, Not set

Sheba Medical Center-ONCOLOGY ( Site 1700), Ramat Gan, Not set

Sourasky Medical Center-Oncology ( Site 1701), Tel Aviv, Not set

Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1113), Roma, Lazio

Ospedale San Raffaele-Oncologia Medica ( Site 1110), Milano, Lombardia

Ospedale San Gerardo-ASST Monza-Research Unit Phase 1 ( Site 1115), Monza, Lombardia

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1114), Rozzano, Milano

Instituto Tumori Giovanni Paolo II-ONCOLOGIA MEDICA ( Site 1112), Bari, Not set

Ospedale Cannizzaro ( Site 1118), Catania, Not set

Istituto Europeo di Oncologia IRCCS-Divisione di Senologia Medica ( Site 1111), Milano, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1116), Napoli, Not set

Istituto Oncologico Veneto IRCCS ( Site 1117), Padova, Not set

Hyogo Medical University Hospital ( Site 2201), Nishinomiya, Hyogo

St. Marianna University School of Medicine Hospital ( Site 2205), Kawasaki, Kanagawa

Kitasato University Hospital ( Site 2204), Sagamihara, Kanagawa

Osaka University Hospital ( Site 2211), Suita, Osaka

Saitama Medical University International Medical Center ( Site 2208), Hidaka-city, Saitama

Tokyo Medical University Hospital ( Site 2206), Shinjuku-ku, Tokyo

Chiba University Hospital ( Site 2212), Chiba, Not set

National Hospital Organization Kyushu Cancer Center ( Site 2209), Fukuoka, Not set

Fukushima Medical University ( Site 2200), Fukushima, Not set

Kumamoto University ( Site 2203), Kumamoto, Not set

St. Luke's International Hospital ( Site 2207), Tokyo, Not set

Juntendo University Hospital ( Site 2210), Tokyo, Not set

National Cancer Center-Center for Breast Cancer ( Site 2404), Goyang-si, Kyonggi-do

Seoul National University Bundang Hospital ( Site 2406), Seongnam, Kyonggi-do

Seoul National University Hospital-Internal Medicine ( Site 2403), Seoul, Not set

Severance Hospital, Yonsei University Health System ( Site 2400), Seoul, Not set

Asan Medical Center ( Site 2402), Seoul, Not set

Samsung Medical Center-Division of Hematology/Oncology ( Site 2401), Seoul, Not set

University Malaya Medical Centre ( Site 2505), Lembah Pantai, Kuala Lumpur

Hospital Pulau Pinang ( Site 2504), George Town, Pulau Pinang

Sarawak General Hospital-Radiotherapy Unit ( Site 2501), Kuching, Sarawak

Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 2506), Kuala Lumpur, Not set

Pantai Hospital Kuala Lumpur-Cancer Centre ( Site 2503), Kuala Lumpur, Not set

Samadhi Centro Oncológico ( Site 0258), México, Distrito Federal

Hospital Civil Fray Antonio Alcalde-Oncology ( Site 0262), Guadalajara, Jalisco

Filios Alta Medicina ( Site 0253), Monterrey, Nuevo Leon

Centro Estatal de Cancerologia-Investigación ( Site 0256), Chihuahua, Not set

Centro de Investigacion Clinica de Oaxaca ( Site 0252), Oaxaca, Not set

Radboudumc-Medical Oncology ( Site 1360), Nijmegen, Gelderland

Maastricht UMC+-Medical Oncology ( Site 1353), Maastricht, Limburg

Jeroen Bosch Hospital ( Site 1359), Den Bosch, Noord-Brabant

Elisabeth-TweeSteden Ziekenhuis-Internal Medicine ( Site 1357), Tilburg, Noord-Brabant

Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL) ( Site 1351), Amsterdam, Noord-Holland

Meander Medisch Centrum ( Site 1358), Amersfoort, Utrecht

Leids Universitair Medisch Centrum-Medical Oncology ( Site 1356), Leiden, Zuid-Holland

Haaglanden MC - locatie Antoniushove-Medical oncology ( Site 1355), Leidschendam, Zuid-Holland

Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1354), Schiedam, Zuid-Holland

East Avenue Medical Center ( Site 0802), Quezon City, National Capital Region

CARDINAL SANTOS MEDICAL CENTER-Research Room ( Site 0800), San Juan, National Capital Region

Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1813), Bydgoszcz, Kujawsko-pomorskie

Pratia MCM Krakow ( Site 1809), Krakow, Malopolskie

Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1818), Siedlce, Mazowieckie

Lux med onkologia sp. z o.o. ( Site 1808), Warsaw, Mazowieckie

Luxmed Onkologia sp. z o. o. ( Site 1820), Warszawa, Mazowieckie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Piersi i Chirurgii (, Warszawa, Mazowieckie

Wojskowy Instytut Medyczny-Klinika Onkologii ( Site 1803), Warszawa, Mazowieckie

Mazowiecki Szpital Onkologiczny-BREAST CANCER ( Site 1821), Wieliszew, Mazowieckie

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1819), Przemysl, Podkarpackie

Bialostockie Centrum Onkologii-Oddzial Onkologii Klinicznej ( Site 1812), Bialystok, Podlaskie

Narodowy Instytut Onkologii - Oddzial w Gliwicach-Breast Unit ( Site 1811), Gliwice, Slaskie

Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1815), Koszalin, Zachodniopomorskie

Champalimaud Foundation ( Site 1006), Lisbon, Lisboa

Centro Hospitalar Universitário Lisboa Norte, E.P.E. - Hospital de Santa Maria ( Site 1004), Lisbon, Lisboa

UNIDADE LOCAL DE SAUDE DE MATOSINHOS ( Site 1007), Matosinhos, Porto

Centro Hospitalar do Porto - Hospital de Santo António-Oncology Service ( Site 1003), Porto, Not set

Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 1005), Porto, Not set

Cardiomed SRL Cluj-Napoca ( Site 2902), Cluj-Napoca, Cluj

Institutul Oncologic-Day Hospital Unit ( Site 2905), Cluj-Napoca, Cluj

Centrul de Oncologie "Sfântul Nectarie"-Medical Oncology ( Site 2901), Craiova, Dolj

Oncopremium Team-Oncology ( Site 2903), Baia Mare, Maramures

Sigmedical Services SRL ( Site 2904), Suceava, Not set

Arkhangelsk Clinical Oncological Dispensary-Chemotherapy department ( Site 1902), Arkhangelsk, Arkhangel Skaya Oblast

Podolsk Regional Clinical Hospital ( Site 1907), Podolsk, Moskovskaya Oblast

Moscow Clinical Research Center-Chemotherapy department ( Site 1903), Moscow, Moskva

Fed State Budgetary Inst N.N. Blokhin Med Center of Oncology MHRF ( Site 1901), Moscow, Moskva

Central Clinical Hospital of the Presidential Administrative Department ( Site 1904), Moscow, Moskva

Nizhegorodsky Regional Oncology Dispensary-chemotherapy ( Site 1912), Nizhniy Novgorod, Nizhegorodskaya Oblast

Ryazan Regional Clinical Oncology Center-Oncology #1 ( Site 1906), Ryazan, Ryazanskaya Oblast

N.N.Petrov Research Institute of Oncology ( Site 1900), Saint Petersburg, Sankt-Peterburg

St. Petersburg Clinical Hospital of Russian Academy Of Sciences-Medical Oncology ( Site 1905), St. Petersburg, Sankt-Peterburg

Hospital Quiron Barcelona ( Site 1326), Barcelona, Cataluna

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 1333), Madrid, Madrid, Comunidad De

Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1320), Madrid, Madrid, Comunidad De

HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1323), Pozuelo de Alarcon, Madrid

Fundación Instituto Valenciano de Oncología-Oncologico ( Site 1332), Valencia, Valenciana, Comunitat

Karolinska Universitetssjukhuset Solna-Tema Cancer - ME Bröst- endokrina tumörer och sarkom ( Site 1, Stockholm, Stockholms Lan

Södra Älvsborg Sjukhus ( Site 1406), Borås, Vastra Gotalands Lan

Ege University Medicine of Faculty ( Site 2004), Bornova, Izmir

I.E.U. Medical Point Hastanesi-Oncology ( Site 2016), Izmir, Karsiyaka, Izmir

Baskent University Dr. Turgut Noyan Research and Training Center ( Site 2013), Adana, Not set

Hacettepe Universitesi-oncology hospital ( Site 2000), Ankara, Not set

Memorial Ankara Hastanesi-Medical Oncology ( Site 2002), Ankara, Not set

Gazi Universitesi-Oncology ( Site 2010), Ankara, Not set

ANKARA ŞEHİR HASTANESİ-Medical Oncology ( Site 2014), Ankara, Not set

Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 2009), Antalya, Not set

Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 2012), Istanbul, Not set

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2005), Istanbul, Not set

İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi-Medical Oncology Department, Malatya, Not set

The Royal Cornwall Hospital ( Site 1507), Truro, Cornwall

Leicester Royal Infirmary-HOPE Clinical Trials Unit ( Site 1502), Leicester, England

St Bartholomew's Hospital ( Site 1508), London, England

The Christie ( Site 1510), Manchester, England

Blackpool Victoria Hospital ( Site 1503), Blackpool, Lancashire

North West Cancer Centre ( Site 1511), Londonderry, London, City Of

Guy's & St Thomas' NHS Foundation Trust ( Site 1501), London, London, City Of

Conditions: Breast Neoplasms

Learn More ›

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT02489903

Completed

This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/26/2025

Locations: Stanford University, Palo Alto, California +9 locations

Conditions: Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer

Learn More ›

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

NCT04083235

Completed

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/26/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama +199 locations

University of Alabama at Birmingham, Birmingham, Alabama

Banner Health- MD Anderson Cancer Center, Gilbert, Arizona

Mayo Clinic - Scottsdale, Phoenix, Arizona

Comprehensive Blood And Cancer Center, Bakersfield, California

University of California- Irvine Health Cancer Cente, Costa Mesa, California

City of Hope National Medical Center, Duarte, California

University of California, Los Angeles (UCLA), Los Angeles, California

St. Jude Hospital Yorba Linda dba St. Joseph Heritage Healthcare, Orange, California

University of California - Irvine Medical Center, Orange, California

Torrance Memorial Physician Network Cancer Care, Redondo Beach, California

Sutter Health Sacramento, Sacramento, California

Presbyterian Intercommunity Hospital (PIH), Whittier, California

UC Health Memorial Hospital, Colorado Springs, Colorado

Rocky Mountain Cancer Center, Denver, Colorado

Mount Sinai Medical Center of Florida, Inc., Miami Beach, Florida

Miami Cancer Institute, Miami, Florida

Florida Cancer Specialists - Fort Myers, Sarasota, Florida

Florida Cancer Specialists - Panhandle, Tallahassee, Florida

Florida Cancer Specialists - St. Petersburg, Tampa, Florida

Florida Cancer Specialists - East, West Palm Beach, Florida

Rush University Medical Center, Chicago, Illinois

Edward Hospital - Elmhurst, Elmhurst, Illinois

Illinois CancerCare - Peoria, Peoria, Illinois

Carle Cancer Center, Urbana, Illinois

Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana

Siouxland Hematology - Oncology Associates, LLP, Sioux City, Iowa

University of Kentucky Markey Cancer Center, Lexington, Kentucky

Pikeville Medical Center, Pikeville, Kentucky

Hematology Oncology Clinic, Baton Rouge, Louisiana

Ochsner Clinic Foundation, New Orleans, Louisiana

Willis-Knighton Cancer Center, Shreveport, Louisiana

Maine Center for Cancer Medicine, Scarborough, Maine

Maryland Oncology Hematology, Silver Spring, Maryland

Beth Israel Deaconess, Boston, Massachusetts

Henry Ford Health System, Detroit, Michigan

Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan

Health Partners Institute, Minneapolis, Minnesota

Mayo Clinic - Rochester, Rochester, Minnesota

Research Medical Center, Kansas City, Missouri

Frontier Cancer Center, Billings, Montana

Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Clinical Research Alliance, Inc, Lake Success, New York

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York

University of Rochester, Rochester, New York

Stony Brook University Medical Center, Stony Brook, New York

Messino Cancer Center, Asheville, North Carolina

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James), Columbus, Ohio

Toledo Clinic Cancer Center, Toledo, Ohio

University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma

Oncology Associates of Oregon, Eugene, Oregon

Compass Oncology - Rose Quarter Cancer Center, Portland, Oregon

Kaiser Permanente - Northwest, Portland, Oregon

Oregon Health & Science University (OHSU), Portland, Oregon

University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh, Pennsylvania

Greenville Hospital System, Greenville, South Carolina

Chattanooga Oncology Hematology Care - Tennessee Oncology, Chattanooga, Tennessee

The West Cancer Center, Memphis, Tennessee

Sarah Cannon and HCA Research Institute, Nashville, Tennessee

Texas Oncology - Austin, Austin, Texas

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

The Center for Cancer and Blood Disorders, Fort Worth, Texas

Baylor College of Medicine, Houston, Texas

Houston Methodist Research Institute, Houston, Texas

MD Anderson Cancer Center, Houston, Texas

Oncology Consultants, Houston, Texas

Texas Oncology - Tyler, Tyler, Texas

Texas Oncology - Wichita Falls, Wichita Falls, Texas

Utah Cancer Specialists, Salt Lake City, Utah

Virginia Cancer Specialists, Fairfax, Virginia

Blue Ridge Cancer Care, Wytheville, Virginia

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin

Bankstown-Lidcombe Hospital, Bankstown, Not set

Monash Medical Centre, Clayton, Not set

Fiona Stanley Hospital, Murdoch, Not set

Sir Charles Gairdner Hospital, Nedlands, Not set

St John of God Subiaco Hospital, Subiaco, Not set

Queen Elizabeth Hospital, Woodville South, Not set

Medizinische Universitaet Graz, Graz, Not set

Ordensklinikum Linz GmbH Barmherzige Schwestern, Linz, Not set

SCRI-CCCIT Gemeinnutzige Gmbh- Gemeinnutzige Salzburger Landeskliniken Betriebsgesmbh, Salzburg, Not set

Medical University of Vienna, Vienna, Not set

Onze-Lieve-Vrouwziekenhuis, Aalst, Not set

ASBL Grand Hôpital de Charleroi (GHdC), Site Notre Dame, Charleroi, Not set

Universitair Ziekenhuis Antwerpen (UZA), Edegem, Not set

University Hospital Gent, Gent, Not set

Hospital centre Jolimont, Haine-Saint-Paul, Not set

University Hospital (UZ) Leuven, Leuven, Not set

University Hospital Mont-Godinne, Yvoir, Not set

Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Not set

Centro Regional Integrado de Oncologia (CRIO), Ceara, Not set

Instituto de Oncologia do Parana - IOP, Curitiba, Not set

Centro de Pesquisas Oncológicas - CEPON, Florianópolis, Not set

Hospital de Caridade de Ijui, Ijuí, Not set

Clinica Neoplasias Litoral, Itajaí, Not set

Hospital Bruno Born, Lajeado, Not set

Centro de Pesquisas Clinicas de Natal - CPCLIN, Natal, Not set

Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Not set

Instituto Nacional Do Cancer (INCA), Rio de Janeiro, Not set

Instituto COI, Rio De Janeiro, Not set

Instituto Brasileiro de Controle do Cancer - IBCC (Sao Paulo), San Paolo, Not set

CIP Centro Integrado de Pesquisas do Hospital de Base, São José Do Rio Preto, Not set

Hospital Alemão Oswaldo Cruz, São Paulo, Not set

Instituto do Cancer do Estado de São Paulo (ICESP), São Paulo, Not set

Alberta Health Services Cross Cancer Institute, Edmonton, Not set

Queen Elizabeth II Health Sciences Centre, Halifax, Not set

McGill University Faculty of Medicine - Royal Victoria Hospital, Montréal, Not set

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Not set

Masarykuv onkologicky ustav, Brno, Not set

Fakultni nemocnice Hradec Kralove, Hradec Králové, Not set

University Hospital Olomouc, Department of Oncology, Olomouc, Not set

Thomayerova Nemocnice, Praha, Not set

CHRU de Tours - Hôpital Trousseau, Chambray-lès-Tours, Not set

Centre Oscar Lambret, Lille, Not set

Hôpital Edouard Herriot, Lyon, Not set

Centre Leon Berard, Lyon, Not set

Hopital Prive Jean Mermoz, Lyon, Not set

Centre Antoine-Lacassagne, Nice, Not set

Hopital Saint Louis, Paris, Not set

CHU Bordeaux - Hopital Haut-Leveque, Pessac, Not set

Centre Hospitalier Universitaire de Poitiers - Poitiers University Hospital, Poitiers Cedex, Not set

Strasbourg Oncologie Liberale, Strasbourg, Not set

Charité - Universitaetsmedizin Berlin, Berlin, Not set

St. Josef-Hospital, Bochum, Not set

Klinikum Esslingen GmbH, Esslingen, Not set

Krankenhaus Nordwest, Frankfurt, Not set

Studiengesellschaft BSF, Halle, Not set

Martin Luther Universitat Halle-Wittenberg, Halle, Not set

Facharztzentrum Eppendorf, Hamburg, Not set

Marienkrankenhaus Hamburg, Hamburg, Not set

Asklepios Klinik Altona, Hamburg, Not set

Medizinische Hochschule Hannover, Hannover, Not set

Slk-Kliniken, Heilbronn, Not set

Klinikum Mannheim, Mannheim, Not set

Krankenhaus St. Franziskus - Kliniken Maria Hilf GmbH, Mönchengladbach, Not set

Universitaetsklinikum Tuebingen, Tuebingen, Not set

Universitaetsklinikum Ulm, Ulm, Not set

Agios Savvas Anticancer Hospital, Athens, Not set

General Hospital of Athens - Laiko, Athens, Not set

National and Kapodistrian University of Athens, Athens, Not set

University General Hospital of Ioannina, Ioánnina, Not set

Theagenion Hospital, Thessaloníki, Not set

Dél-pesti Centrumkórház - Szent László Kórház telephely, Budapest, Not set

Országos Onkológiai Intézet, Budapest, Not set

Semmelweis Egyetem Belgyógyászati és Hematológiai Klinika, Budapest, Not set

Debreceni Egyetem Klinikai Kozpont, Debrecen, Not set

Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvár, Not set

Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelointézet, Szolnok, Not set

Soroka Medical Center, Beer Sheva, Not set

Rambam Health Care Campus, Haifa, Not set

Policlinico S. Orsola-Malpighi, Bologna, Not set

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Not set

Istituto Europeo di Oncologia, Milano, Not set

Azienda Ospedaliero-Universitaria di Modena, Modena, Not set

AUSL di Piacenza-Ospedale Guglielmo Da Saliceto, Piacenza, Not set

Azienda Ospedaliero Universitaria Pisana, Pisa, Not set

AOU Ospedali Riuniti di Ancona, Torrette, Not set

Azienda Ospedaliera - Universitaria Integrata di Verona - Ospedale Borgo Roma, Verona, Not set

Inje University Haeundae Paik Hospital, Busan, Not set

National Cancer Center, Goyang-si, Not set

CHA Bundang Medical Center, Gyeonggi-do, Not set

Asan Medical Center, Seoul, Not set

Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Not set

Korea University Guro Hospital, Seoul, Not set

Hospital de Braga, Braga, Not set

Centro Hospitalar Universitario de Lisboa Norte - Hospital de Santa Maria, Lisboa, Not set

Champalimaud Cancer Center, Lisbon, Not set

Unidade Local de Saude Matosinhos E.P.E. Hospital Pedro Hispano, Senhora da Hora, Not set

Centro Hospitalar de Vila Nova de Gaia/Espinho EPE, Vila Nova de Gaia, Not set

Evimed LLC, Chelyabinsk, Not set

Limited Liability Company- Clinica Druzhkovyh, Kazan, Not set

Kursk Regional Clinical Oncology Dispensary, Kursk, Not set

Main Military Clinical Hospital named after N.N. Burdenko, Moscow, Not set

Volga District Medical Centre, Novgorod, Not set

Federal State Budgetary Institution - Russian Scientific Center of Radiology and Surgical Technologies n.a. academician A.M.Granov, Saint-Petersburg, Not set

Hospital General Universitario de Elche, Alicante, Not set

Hospital Universitario de Badajoz, Badajoz, Not set

Hospital Germans Trias i Pujol, Badalona, Not set

Hospital Quironsalud Barcelona, Barcelona, Not set

Hospital de la Santa Creu i Sant Pau Barcelona, Barcelona, Not set

Hospital Vall D Hebron, Barcelona, Not set

Hospital Clinic Barcelona, Barcelona, Not set

Corporacio Sanitaria Parc Tauli - Hospital de Sabadell, Barcelona, Not set

Institut Catala d'Oncologia - L'Hospitalet, Barcelona, Not set

Complejo Hospitalario Universitario de Granada - Hospital Universitario Virgen de las Nieves, Granada, Not set

Hospital General Universitario Gregorio Marañon, Madrid, Not set

Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Centro Integral Oncologico Clara Campal, Madrid, Not set

Hospital Regional Universitario de Malaga, Málaga, Not set

Complejo Hospitalario de Navarra, Pamplona, Not set

Hospital Universitario Marques de Valdecilla, Santander, Not set

Hospital Universitario Miguel Servet, Zaragoza, Not set

Guy's and St. Thomas' NHS Foundation Trust, London, Not set

Royal Marsden Foundation Trust, London, Not set

Imperial College Healthcare NHS Trust, London, Not set

Cancer Research UK - Christie Hospital Foundation NHS Trust - Dept of Medical Oncology, Manchester, Not set

Nottingham City Hospital, Nottingham, Not set

Conditions: Metastatic Adenocarcinoma of the Pancreas

Learn More ›

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

NCT05075993

Active Not Recruiting

This is an investigator-initiated industry-supported phase 1 clinical trial conducted in the phase 1 clinic at The University of Texas MD Anderson Cancer Center who will hold the Investigational New Drug (IND). Lvygen Biopharma will provide as investigational supply LVGN3616, LVGN6051 and LVGN7409 at no cost to the patients on this study. This study will explore antitumor activity of four LVGN3616 and LVGN6051 based regimens in seven selected tumor types:

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/26/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic HPV Related Solid Tumors, Metastatic Ovarian Carcinoma, Metastatic Soft Tissue Sarcoma, Metastatic Uveal Melanoma

Learn More ›

Combination of Serabelisib and Insulin Suppressing Diet with or Without Nab-paclitaxel in Subjects with Advanced Solid Tumors with PIK3CA Mutations

NCT05300048

Active Not Recruiting

This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/25/2025

Locations: University of Alabama, Birmingham, Alabama +16 locations

Conditions: Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation

Learn More ›

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

NCT05020860

Recruiting

The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving chemotherapy prior to surgery.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/25/2025

Locations: Harris Health System - Smith Clinic, Houston, Texas +1 locations

Conditions: Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer

Learn More ›

Browse by State

Paclitaxel treatment options in Alabama

Paclitaxel treatment options in Alaska

Paclitaxel treatment options in Arizona

Paclitaxel treatment options in Arkansas

Paclitaxel treatment options in California

Paclitaxel treatment options in Colorado

Paclitaxel treatment options in Connecticut

Paclitaxel treatment options in Delaware

Paclitaxel treatment options in District of Columbia

Paclitaxel treatment options in Florida

Paclitaxel treatment options in Georgia

Paclitaxel treatment options in Hawaii

Paclitaxel treatment options in Idaho

Paclitaxel treatment options in Illinois

Paclitaxel treatment options in Indiana

Paclitaxel treatment options in Iowa

Paclitaxel treatment options in Kansas

Paclitaxel treatment options in Kentucky

Paclitaxel treatment options in Louisiana

Paclitaxel treatment options in Maine

Paclitaxel treatment options in Montana

Paclitaxel treatment options in Nebraska

Paclitaxel treatment options in Nevada

Paclitaxel treatment options in New Hampshire

Paclitaxel treatment options in New Jersey

Paclitaxel treatment options in New Mexico

Paclitaxel treatment options in New York

Paclitaxel treatment options in North Carolina

Paclitaxel treatment options in North Dakota

Paclitaxel treatment options in Ohio

Paclitaxel treatment options in Oklahoma

Paclitaxel treatment options in Oregon

Paclitaxel treatment options in Maryland

Paclitaxel treatment options in Massachusetts

Paclitaxel treatment options in Michigan

Paclitaxel treatment options in Minnesota

Paclitaxel treatment options in Mississippi

Paclitaxel treatment options in Missouri

Paclitaxel treatment options in Pennsylvania

Paclitaxel treatment options in Rhode Island

Paclitaxel treatment options in South Carolina

Paclitaxel treatment options in South Dakota

Paclitaxel treatment options in Tennessee

Paclitaxel treatment options in Texas

Paclitaxel treatment options in Utah

Paclitaxel treatment options in Vermont

Paclitaxel treatment options in Virginia

Paclitaxel treatment options in Washington

Paclitaxel treatment options in West Virginia

Paclitaxel treatment options in Wisconsin

Paclitaxel treatment options in Wyoming